A series of novel diphenyl methanol carbamate (DPM) derivatives as acetyl cholinesterase inhibitors for Alzheimer’s disease were designed docked and synthesized. Molecular docking studies revealed that the binding of DPM derivatives were better as compared to standard drug rivastigmine. The synthesized compounds were further subjected to enzymatic assay for AChE inhibition where compound 3g exhibited potent in-vitro inhibitory activity against AChE having(20.65 μM) IC50 value. Further in silico screening was carried out to predict ADME parameters including drug likeliness. Compound 3g was found to be within drug likeliness range having 3.12 logP. Therefore, compound 3g can be considered as a promising molecule for further development of novel compound as anti-Alzheimer’s agents.